Navigation Links
Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
Date:1/31/2011

EAST BRUNSWICK, N.J., Jan. 31, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced its intention to offer, subject to market conditions and other factors, $125 million aggregate principal amount of Convertible Senior Notes due 2018 (the "Notes") pursuant to an automatically effective registration statement filed with the Securities and Exchange Commission today. Savient also intends to grant the underwriters an option to purchase up to an additional $18.75 million aggregate principal amount of Notes, solely to cover over-allotments. The interest rate, conversion price and other terms of the Notes will be determined by negotiations between Savient and the underwriters.

Savient expects to use the net proceeds of the offering to commercialize KRYSTEXXA™ in the United States, including completion of its ongoing efforts to recruit a sales force, expand its marketing organization and establish a commercial infrastructure, to fund clinical development activities directed to potential label expansion for KRYSTEXXA in the United States, to further develop and seek regulatory approval for KRYSTEXXA in jurisdictions outside the United States, particularly in the European Union, and for general corporate purposes, including working capital.

J. P. Morgan Securities LLC is acting as sole book-running manager of the offering. Lazard Capital Markets LLC is acting as a co-manager of the offering. A copy of the prospectus meeting the requirements of Section 10 of the Securities Act of 1933 may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; Telephone (631) 254-1735.

This press release is neither an offer to sell nor a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
(Date:10/17/2014)... OAKS, Calif. , Oct. 17, 2014  Amgen ... of R. Sanders Williams , M.D., president of ... Mahley Distinguished Professor.  "We are pleased ... Amgen Board," said Robert A. Bradway , chairman ... and distinguished experience in academic medicine and his direct ...
(Date:10/17/2014)... , October 17, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has announced ... Monitor : North American Automated External ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The report ... 2008-2018 analyzes the market of devices ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... October 20, 2014 Final Cut Pro X ... of the Citrus theme for FCPX filmmakers . , ... to describe the Citrus theme” Says Christina Austin, CEO of ... look so professional.” , Citrus comes with all the tools ... template are: four transitions for added style, a title screen ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
(Date:10/19/2014)... Visual Impact Frequency Training - a ... to the public generating a frenzied buzz of ... community. The commotion surrounding the program's launch has ... an investigative review. , "Many gym-goers are familiar ... known as a training 'plateau' where they are ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... ALEXANDRIA, Va., Sept. 24 - An editorial,published ... Dental Research (JDR),focuses on the global theme issue ... for Dental Research (IADR) President,Deborah Greenspan and IADR ... of Orofacial Sciences, School of Dentistry, The AIDS ...
... Companies Investing in R&D Shows Revenue Derived ... of Total Revenue in 2006, PHILADELPHIA and ... International Ltd. (CMR), a Thomson business, today,announced it ... an indispensable reference and business planning tool for,decision ...
... announced today that the U.S. Food and Drug ... 360(TM) Orbital Atherectomy System (OAS),for removing plaque blockages ... device offers a promising new alternative for treating ... Disease,PAD. The clearance follows the successful completion ...
... the Institute of Bioengineering and Nanotechnology (IBN), Institute of ... Singapore (GIS) have successfully developed a miniaturized device that ... flu (H5N1) virus. , If successfully commercialized, this ... surveillance of nascent avian flu epidemic. , According to ...
... The Iacocca Foundation and S.E.VEN, BOSTON, Sept. 24 ... has added finding a cure for diabetes and,alleviating world ... of The,Iacocca Foundation and S.E.VEN. "As communicators, we ... not driven by dollars, but by a commitment,to truly ...
... Md., Sept. 24 MedImmune, Inc. announced,today that ... to GlaxoSmithKline to support the development and construction ... vaccines. Reverse,genetics is a method by which viruses ... DNA. For potential pandemic influenza vaccines, reverse,genetics can ...
Cached Medicine News:Health News:Dental Researchers Participate in Global Awareness Initiative 2Health News:2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available 2Health News:2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available 3Health News:New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours 2Health News:New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours 3Health News:Lab-on-chip testing for 'bird flu' developed by Singapore scientists 2Health News:Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts 2Health News:MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production 2
... AvantGard Low Binding 20l Barrier Tips. Low ... DNA and proteins bound to the tip. Most ... which means the focus is on liquid not ... focuses on low binding which reduces the binding ...
... tips eliminate false signals and contamination ... tested, Promega Barrier Tips offer performance ... nucleic acids (PCR(a)), radioactive isotopes, tissue ... serological specimens. , ,Promega Barrier Tips ...
... Aerosol Resistant Tips offer a safe alternative ... are designed for applications such as PCR(a), ... addition, ART Tips are excellent for tissue ... studies. ART Tips prevent aerosol contaminants and ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
Medicine Products: